Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTT-705 with Pravastatin in Type II Hyperlipidemia
NCT00688896Phase 2Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Jun 2002
- Primary completion
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dalcetrapib in hyperlipidemia (3 arms), sponsored by Akros Pharma Inc. Primary endpoints: Percent change from baseline in HDL-C at 4 weeks and Inhibition of CETP activity at 4 weeks. Started Jun 2002; status: completed.
02
Drugs
dalcetrapib
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT00688896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00688896.